newsfilter
← Latest News
GlobeNewswire·

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R